Report overview
Hepatitis C is a contagious liver disease caused due to hepatitis C virus. Hepatitis C damages and infects the liver. Hepatitis C is spread as the infected blood comes in contact with non-infected blood. Ranging in severity hepatitis C can cause acute and chronic hepatitis infection. Chronic hepatitis C is diagnosed by liver biopsy and blood tests. According to World Health Organization (WHO), globally 130 million to 150 million people are suffering from chronic hepatitis C. Hepatitis C is treated with antiviral drugs to inhibit the growth of virus and prevent liver damage. According to World Health Organization (WHO), 50% to 90% of people suffering from hepatitis C are treated with antiviral treatment.
This report contains market size and forecasts of Hepatitis C Virus (HCV) Antiviral in Global, including the following market information:
Global Hepatitis C Virus (HCV) Antiviral Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hepatitis C Virus (HCV) Antiviral market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
HCV Antibody Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hepatitis C Virus (HCV) Antiviral include Roche Diagnostics, Abbott, Siemens, Qiagen, bioM?rieux, Bio-Rad Laboratories, Meridian Bioscience, Vista Diagnostics and Biogate Laboratories, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hepatitis C Virus (HCV) Antiviral companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hepatitis C Virus (HCV) Antiviral Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hepatitis C Virus (HCV) Antiviral Market Segment Percentages, by Type, 2021 (%)
HCV Antibody
HCV Viral Load
HCV Genotyping
Global Hepatitis C Virus (HCV) Antiviral Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hepatitis C Virus (HCV) Antiviral Market Segment Percentages, by Application, 2021 (%)
Diagnostic Centers
Hospitals
Home Use
Global Hepatitis C Virus (HCV) Antiviral Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hepatitis C Virus (HCV) Antiviral Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hepatitis C Virus (HCV) Antiviral revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hepatitis C Virus (HCV) Antiviral revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche Diagnostics
Abbott
Siemens
Qiagen
bioM?rieux
Bio-Rad Laboratories
Meridian Bioscience
Vista Diagnostics
Biogate Laboratories
J.Mitra & Co. Ltd
Siemens Medical
General Biologicals
